| 2/23/2015 | CVLM | Merck gets no tenders in offer for three series of Cubist convertibles
|
| 1/22/2015 | CVLM | Merck tenders for three series of Cubist convertibles following merger
|
| 1/14/2015 | CV | Market Commentary: Morning Commentary: Tesla down outright, up on hedge; Southwestern Energy mandatory oversubscribed
|
| 1/13/2015 | CV | Market Commentary: Health care names better bid; Brocade extends dollar-neutral gain; Aegean Marine rises
|
| 12/22/2014 | CV | Market Commentary: Gilead drops in line with shares on Express Scripts news; MGM weaker; recent deals trade
|
| 12/9/2014 | CV | Market Commentary: Cubist trades down after patent setback; Energy XXI drops; IGI Laboratories launches deal
|
| 12/9/2014 | CV | Market Commentary: Morning Commentary: Planned T-Mobile eyed; Envestnet, Fiat also on tap; Cubist slips
|
| 12/8/2014 | CV | Market Commentary: Cubist gains outright, falls on swap on Merck takeout; T-Mobile, Envestnet deals on tap
|
| 12/8/2014 | BKCVIG | Merck to issue $9.5 billion of debt to acquire Cubist Pharmaceuticals
|
| 12/8/2014 | CV | Market Commentary: Morning Commentary: Cubist jumps outright, falls on swap on Merck takeout; Cobalt down again
|
| 8/27/2014 | CV | Market Commentary: Aegerion adds on swap with higher shares; Titan Machinery slips on swap on lower shares
|
| 8/21/2014 | CV | Market Commentary: Convertibles trade quietly, flat on hedge; Priceline unchanged; Photronics shares higher
|
| 8/21/2014 | CV | Market Commentary: Morning Commentary: Convertibles trade quietly; Priceline flat; Cubist active with shares higher
|
| 7/23/2014 | CV | Market Commentary: Earnings spur activity; Xilinx drops outright, expands on hedge; Cubist adds on hedge
|
| 7/23/2014 | CV | Market Commentary: Morning Commentary: Earnings in focus; Cubist in line; Xilinx convertibles down sharply
|
| 4/22/2014 | CV | Market Commentary: Earnings drive convertibles action; Medidata tanks outright, adds on hedge; Rambus in line
|
| 12/31/2013 | CV | Outlook 2014: U.S. primary market looks stronger after 'turning a corner' in Q4; terms may cheapen
|
| 10/24/2013 | CV | Market Commentary: New SanDisk edges up; existing SanDisk recovers; Covanta plunges outright, adds on hedge
|
| 9/25/2013 | CV | Market Commentary: Maiden mandatory prices at the mids; deal eyed as cheap ahead of terms; Rallye prices
|
| 9/10/2013 | CV | Cubist Pharmaceuticals greenshoes up convertible sales to $800 million
|
| 9/6/2013 | CV | Market Commentary: Convertibles end week on a quiet note; new Cubist issues little changed; Liberty bid 'marginally higher'
|
| 9/5/2013 | CV | New Issue: Cubist Pharmaceuticals prices upsized $700 million convertibles in two tranches
|
| 9/5/2013 | CV | Market Commentary: Cubist's two new tranches add on debut; Liberty exchangeable softens; Affymetrix slips
|
| 9/4/2013 | CV | Cubist's planned convertible notes upsized to $700 million; talk tightened on both tranches
|
| 9/4/2013 | CV | Market Commentary: New Liberty exchangeable expands on hedge; Cubist upsizes, tightens talk; Navistar slips
|
| 9/3/2013 | CV | Cubist plans $600 million of convertible bonds in two tranches
|
| 9/3/2013 | CV | Market Commentary: Convertibles mostly quiet post-break; Qihoo adds outright, on hedge; Cubist plans $600 million
|
| 7/31/2013 | CV | Market Commentary: Convertibles trade sideways, better amid unchanged Fed policy; NuVasive down; Meritor up
|
| 5/21/2013 | CV | Market Commentary: Cubist, Health Care REIT trade up in line with shares; Tesla extends drop; NetApp active
|
| 1/20/2012 | CV | Market Commentary: Convertibles turn quiet: Kinross Gold steady; Cogent quiet despite share slump; Kodak adds
|
| 11/14/2011 | CV | Market Commentary: Central European Distribution, Savient extend losses; Newer Human Genome premium rises
|
| 10/20/2011 | CV | Market Commentary: Cubist improves dollar neutral; Ingersoll-Rand drops; low-premium names 'better for sale'
|
| 10/6/2011 | CV | Market Commentary: Convertibles improve; beaten down DryShips, AMR rebound; Bank of America paper in focus
|
| 9/30/2011 | CV | Market Commentary: Convertibles sell off; GMX, MGM trade lower; Kodak drops sharply on restructuring fears
|
| 9/9/2011 | CV | Market Commentary: Convertibles under pressure as equities drop; Amerigroup, RadioShack lower; Dendreon flat
|
| 8/30/2011 | CV | Market Commentary: Kodak improves dollar neutral after CEO comments; Cubist paper adds; Radian extends gains
|
| 7/11/2011 | CV | Market Commentary: Convertibles sink with drop in equities; Virgin Media, Coinstar slip; Alcoa earnings eyed
|
| 6/29/2011 | CV | Market Commentary: Liquid names in trade; U.S. Steel lags underlying shares; Cameron trades ahead of call
|
| 5/27/2011 | CV | Market Commentary: Salesforce ends week slightly better; MannKind trades as shares creep up; Cubist mixed
|
| 5/26/2011 | CV | Market Commentary: Akorn trades up on debut; NetApp gains outright after raised guidance; Cubist in action
|
| 5/24/2011 | CV | Market Commentary: Cubist flat to lower amid takeover chatter; Medtronic 'for sale' after disappointing earnings
|
| 4/5/2011 | CV | Market Commentary: Cubist mixed dollar neutral after Teva agreement; Ciena mixed; Horizon Lines recoups some
|
| 12/3/2010 | CV | Market Commentary: Clearwire slumps on debut as hedge players steer clear; Vertex below par; Cameron rises
|
| 10/25/2010 | CV | Cubist Pharmaceuticals $50 million greenshoe exercised in full
|
| 10/22/2010 | CV | Market Commentary: SanDisk higher after earnings; ViroPharma up 0.5 point on swap; new Cubist moves above par
|
| 10/21/2010 | CV | Market Commentary: Cubist, Amylin in focus, unchanged in trade; Alliance Data, Covanta steady after earnings
|
| 10/20/2010 | CV | Market Commentary: New Cubist trades slightly over par; Amylin gets slammed but pares losses; Gilead quiet
|
| 10/19/2010 | CV | Market Commentary: Cubist's upsized $400 million convertibles price, seen 1% cheap before pricing; EMC mixed
|
| 10/19/2010 | CV | New Issue: Cubist prices upsized $400 million seven-year convertibles to yield 2.5%, up 25%
|
| 10/18/2010 | CV | Cubist to price $250 million seven-year convertibles to yield 2.25%-2.75%, up 22.5%-27.5%
|
| 10/18/2010 | CV | Market Commentary: NII Holdings flat to lower on scuttled wireless agreement; EMC mixed; Cubist deal on tap
|
| 8/7/2009 | CV | Market Commentary: Onyx, Rayonier price rich, jump; D.R. Horton up with sector; Cubist gets pre-conference boost
|
| 7/20/2009 | CV | Market Commentary: Human Genome surges on lupus trial; Lincare trades before earnings; CIT busy; Intel to price
|
| 2/10/2009 | CV | Market Commentary: Financials lower after bank plan; other convertibles hold up as equities slide; AMD steady
|
| 1/23/2009 | CV | Market Commentary: Convertibles bounce around; selling hits Nabors, Transocean, AMD; Cubist up on earnings; Wyeth up
|
| 2/7/2008 | CV | Cubist buys back $50 million of 2.25% convertibles
|
| 6/29/2006 | CV | Market Commentary: Red Hat rises dollar-neutral, falls outright; new Vector bid higher; CNET, Intel gain; Nexans prices deal
|
| 6/26/2006 | CV | Market Commentary: Intel, Amgen under pressure; Inco rises; Chesapeake launches mandatories offering
|
| 6/8/2006 | BTCV | Cubist Pharmaceuticals to redeem 5.5% convertibles due 2008
|
| 6/5/2006 | BTCV | Cubist Pharmaceuticals greenshoe exercised, raising convertibles issue to $350 million
|
| 6/2/2006 | CV | Market Commentary: Trinity gains on debut; Novell improves further on volatility, takeover speculation; Encysive gains outright
|
| 6/1/2006 | CV | Market Commentary: Cubist stacks up well on debut; Novell holds up against weak guidance; Trinity gains in the gray
|
| 6/1/2006 | BTCV | New Issue: Cubist prices upsized $325 million seven-year convertibles at 2.25%, up 30%
|
| 5/31/2006 | BTCV | Cubist prices upsized $325 million of convertibles at 2.25%, up 30%
|
| 5/31/2006 | CV | Market Commentary: Cubist climbs in gray market; L-3 improves on stock downgrade; Novell seen to firm on poor guidance
|
| 5/30/2006 | CV | Market Commentary: CA up dollar-neutral amid delayed earnings; Level 3 deal seen as attractive; Cubist plans deal as expected
|
| 5/30/2006 | BTCV | Cubist to price $275 million of 7-year convertibles, talked at 2.25%-2.75%, up 25%-30%
|
| 5/26/2006 | CV | Market Commentary: Credence firm despite downgrades; Cubist gains on FDA approval; Nabors, Transocean up with stocks
|
| 5/2/2005 | CV | Market Commentary: Corixa converts climb to par on takeover, other biotechs mixed; Calpine higher; Primus plunges
|
| 7/5/2002 | CV | Market Commentary: Convertibles marked higher in very thin post-holiday session
|
| 12/24/2001 | CV | Cubist Pharmaceuticals says greenshoe exercised, raising convertibles to $165 million
|
| 10/24/2001 | CV | Market Commentary: Convertible market higher as $1 bln in new deals emerge
|
| 10/23/2001 | CV | New Issue: Cubist Pharma $125 mln convertibles at 5.5% yield, up 10%
|
| 10/23/2001 | CV | Market Commentary: Convertible market flat to higher as stocks dip
|
| 10/22/2001 | CV | Market Commentary: Convertibles gain with stocks, new deals keep coming
|
| 10/22/2001 | CV | Cubist Pharma $125 mln converts talked at 5.0%-5.25% yield, 10%-15%% premium
|
